Relief for Future Mothers: Long-Awaited Morning Sickness Medication Finally Coming to Japan

Nearly a decade after its approval in the United States and widespread use in over 40 countries, a dedicated morning sickness medication is finally set to be introduced in Japan. Mochida Pharmaceutical has announced a contract with a Canadian firm to begin clinical trials, aiming for a domestic launch by 2030. The news has sparked a massive wave of reactions on social media.

For years, Japan has grappled with the issue of "drug loss"—a phenomenon where new medications approved abroad remain unavailable domestically. Despite the long-standing track record of this morning sickness drug in the U.S., its absence in Japan led many online commenters to criticize the delay as a reflection of a societal mindset that "women should naturally endure suffering" during pregnancy.

Following Mochida Pharmaceutical's announcement, former patients who suffered from severe morning sickness (hyperemesis gravidarum) shared harrowing accounts of their experiences. "It was so painful I was sleeping next to my own vomit," one user shared, while others expressed relief that "future pregnant women will finally be saved." Mochida Pharmaceutical, already well-known for its "Collage Furufur" skincare line, has further solidified its reputation as a champion for women's health through this move.

The company’s recent financial reports show strong performance in new drugs and biosimilars, leading to increased revenue and profits. This financial stability is allowing the firm to accelerate investments in areas with high social impact. As Japan faces an urgent need to address its declining birthrate, many are calling for the government to provide more support for initiatives that reduce the physical and mental burdens of pregnancy, rather than focusing solely on childcare subsidies.

The Context

In Japan, the term "drug loss" (or drug lag) refers to the significant delay in the availability of pharmaceuticals that are already standard treatments in other developed nations. This delay is often attributed to Japan's rigorous and time-consuming clinical trial requirements for domestic approval. Furthermore, Japanese culture has historically emphasized "gaman" (endurance), which some activists argue has led to a slower adoption of medical interventions for conditions like morning sickness or labor pain, which are often viewed as inevitable parts of motherhood. Mochida Pharmaceutical, a mid-sized Japanese company specializing in obstetrics, gynecology, and dermatology, is taking a significant step toward changing this landscape.